ArticleEClinicalMedicine2022

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.

Emanuele Nicastri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.